CA3159575A1 - Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure - Google Patents

Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure

Info

Publication number
CA3159575A1
CA3159575A1 CA3159575A CA3159575A CA3159575A1 CA 3159575 A1 CA3159575 A1 CA 3159575A1 CA 3159575 A CA3159575 A CA 3159575A CA 3159575 A CA3159575 A CA 3159575A CA 3159575 A1 CA3159575 A1 CA 3159575A1
Authority
CA
Canada
Prior art keywords
patient
terlipressin
days
hrs
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3159575A
Other languages
English (en)
French (fr)
Inventor
Khurram Jamil
Stephen Chris Pappas
Peter TEUBER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Hospital Products IP Unlimited Co
Original Assignee
Jamil Khurram
Teuber Peter
Mallinckrodt Hospital Products IP Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jamil Khurram, Teuber Peter, Mallinckrodt Hospital Products IP Unlimited Co filed Critical Jamil Khurram
Publication of CA3159575A1 publication Critical patent/CA3159575A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CA3159575A 2019-10-30 2020-10-29 Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure Pending CA3159575A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962928152P 2019-10-30 2019-10-30
US62/928,152 2019-10-30
PCT/IB2020/060185 WO2021084483A1 (en) 2019-10-30 2020-10-29 Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure

Publications (1)

Publication Number Publication Date
CA3159575A1 true CA3159575A1 (en) 2021-05-06

Family

ID=73060034

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3159575A Pending CA3159575A1 (en) 2019-10-30 2020-10-29 Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure

Country Status (10)

Country Link
US (1) US20210128676A1 (https=)
EP (1) EP4051310A1 (https=)
JP (1) JP2023500654A (https=)
KR (1) KR20220092868A (https=)
CN (1) CN114980914A (https=)
AU (1) AU2020373408A1 (https=)
BR (1) BR112022006329A2 (https=)
CA (1) CA3159575A1 (https=)
MX (1) MX2022004157A (https=)
WO (1) WO2021084483A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240019089A (ko) * 2021-06-07 2024-02-14 말린크로트 파마슈티칼스 아일랜드 리미티드 간신장 증후군 1형 환자의 치료 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015203036A1 (en) * 2010-07-14 2015-07-02 Cumberland Emerging Technologies, Inc Methods of Treating Hepatorenal Syndrom and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
US10335452B2 (en) * 2014-10-24 2019-07-02 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1

Also Published As

Publication number Publication date
EP4051310A1 (en) 2022-09-07
US20210128676A1 (en) 2021-05-06
MX2022004157A (es) 2022-07-19
JP2023500654A (ja) 2023-01-10
CN114980914A (zh) 2022-08-30
KR20220092868A (ko) 2022-07-04
AU2020373408A1 (en) 2022-04-21
BR112022006329A2 (pt) 2022-08-16
WO2021084483A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
JP7346494B2 (ja) １型肝腎症候群患者の治療方法
AU2014256944B2 (en) Compositions and methods for treating renal failure
US20240374675A1 (en) Method of treating patients with hepatorenal syndrome type 1
CN111920939A (zh) 血管紧张素ii单独或以组合方式用于治疗低血压
US20220143132A1 (en) Method of treating patients with hepatorenal syndrome type 1
US20210128676A1 (en) Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure
US20200237856A1 (en) Method of treating patients with hepatorenal syndrome type 1
KR20120089623A (ko) 정맥내 투여용 이부프로펜을 이용한 환자의 치료
KR20240019089A (ko) 간신장 증후군 1형 환자의 치료 방법
CA2910601C (en) Compositions and methods for treating renal failure

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241025

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241025

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241025

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251024

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202